ArticleBiomedicines2022

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center.

Seung-Won Jung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.